3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
163
Endometrial Neoplasms
13
Ovarian Neoplasms
12
Fallopian Tube Neoplasms
5
Recurrence
4
Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Intraductal, Noninfiltrating
4
Triple Negative Breast Neoplasms
3
Breast Diseases
3
Breast Cancer Metastatic
3
Prostatic Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Lobular
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Polycystic Ovary Syndrome
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Pain
1
Osteoporosis
1
Neoplastic Cells, Circulating
1
Neoadjuvant Operable Breast Cancer
1
Multiple Endocrine Neoplasia Type 1
1
Medullary cystic kidney disease 1
1
Lymphangioleiomyomatosis
1
Interventions
Trastuzumab
5
Carboplatin
4
toripalimab
2
pertuzumab
2
pembrolizumab
2
Tretinoin
2
Paclitaxel
2
Immunotherapy
2
Drug Therapy
2
Doxorubicin
2
Docetaxel
2
Cytarabine
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
venetoclax
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
temsirolimus
1
talazoparib
1
tagraxofusp
1
sarilumab
1
sargramostim
1
pyrotinib
1
pexidartinib
1
pazopanib
1
patritumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pathologic Complete Response
×
Letrozole
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled